Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Osteoglycin - A switch from angiogenesis to T-cell recruitment?

Dimberg A.

EBioMedicine. 2018 Sep;35:22-23. doi: 10.1016/j.ebiom.2018.08.020. Epub 2018 Aug 17. No abstract available.

2.

Region-by-region analysis of PET, MRI, and histology in en bloc-resected oligodendrogliomas reveals intra-tumoral heterogeneity.

Roodakker KR, Alhuseinalkhudhur A, Al-Jaff M, Georganaki M, Zetterling M, Berntsson SG, Danfors T, Strand R, Edqvist PH, Dimberg A, Larsson EM, Smits A.

Eur J Nucl Med Mol Imaging. 2018 Aug 14. doi: 10.1007/s00259-018-4107-z. [Epub ahead of print]

PMID:
30109401
3.

Re-exploration for bleeding associated with increased incidence of the need for reintervention after coronary artery bypass graft surgery.

Dimberg A, Alström U, Janiec M.

Interact Cardiovasc Thorac Surg. 2018 Aug 7. doi: 10.1093/icvts/ivy245. [Epub ahead of print]

PMID:
30101308
4.

Bones in human CYP26B1 deficiency and rats with hypervitaminosis A phenocopy Vegfa overexpression.

Lind T, Lugano R, Gustafson AM, Norgård M, van Haeringen A, Dimberg A, Melhus H, Robertson SP, Andersson G.

Bone Rep. 2018 Jun 21;9:27-36. doi: 10.1016/j.bonr.2018.06.006. eCollection 2018 Dec.

5.

IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.

Zhang L, He L, Lugano R, Roodakker K, Bergqvist M, Smits A, Dimberg A.

Neuro Oncol. 2018 Oct 9;20(11):1505-1516. doi: 10.1093/neuonc/noy088.

6.

Higher Preoperative Plasma Thrombin Potential in Patients Undergoing Surgery for Aortic Stenosis Compared to Surgery for Stable Coronary Artery Disease.

Dimberg A, Alström U, Ståhle E, Christersson C.

Clin Appl Thromb Hemost. 2018 Nov;24(8):1282-1290. doi: 10.1177/1076029618776374. Epub 2018 May 16.

PMID:
29768939
7.

Consensus guidelines for the use and interpretation of angiogenesis assays.

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW.

Angiogenesis. 2018 May 15. doi: 10.1007/s10456-018-9613-x. [Epub ahead of print] Review.

8.

CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.

Lugano R, Vemuri K, Yu D, Bergqvist M, Smits A, Essand M, Johansson S, Dejana E, Dimberg A.

J Clin Invest. 2018 Aug 1;128(8):3280-3297. doi: 10.1172/JCI97459. Epub 2018 Jun 25.

9.

Erratum to: "No improvements in long-term outcome after coronary artery bypass grafting with arterial grafts as a second conduit: a Swedish nationwide registry study" [Eur J Cardiothorac Surg 2018;53(2):448-454].

Janiec M, Dimberg A, Nazari Shafti TZ, Lagerqvist B, Lindblom RPF.

Eur J Cardiothorac Surg. 2018 May 1;53(5):1098. doi: 10.1093/ejcts/ezy123. No abstract available.

PMID:
29534169
10.

Graft failure and recurrence of symptoms after coronary artery bypass grafting.

Janiec M, Nazari Shafti TZ, Dimberg A, Lagerqvist B, Lindblom RPF.

Scand Cardiovasc J. 2018 Jun;52(3):113-119. doi: 10.1080/14017431.2018.1442930. Epub 2018 Mar 6. Erratum in: Scand Cardiovasc J. 2018 Jun;52(3):170.

PMID:
29508655
11.

No improvements in long-term outcome after coronary artery bypass grafting with arterial grafts as a second conduit: a Swedish nationwide registry study.

Janiec M, Dimberg A, Nazari Shafti TZ, Lagerqvist B, Lindblom RPF.

Eur J Cardiothorac Surg. 2017 Aug 28. doi: 10.1093/ejcts/ezx280. [Epub ahead of print] Erratum in: Eur J Cardiothorac Surg. 2018 May 1;53(5):1098.

PMID:
28958083
12.

Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice.

Cedervall J, Dragomir A, Saupe F, Zhang Y, Ärnlöv J, Larsson E, Dimberg A, Larsson A, Olsson AK.

Oncoimmunology. 2017 Apr 20;6(8):e1320009. doi: 10.1080/2162402X.2017.1320009. eCollection 2017.

13.

Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Eriksson E, Milenova I, Wenthe J, Ståhle M, Leja-Jarblad J, Ullenhag G, Dimberg A, Moreno R, Alemany R, Loskog A.

Clin Cancer Res. 2017 Oct 1;23(19):5846-5857. doi: 10.1158/1078-0432.CCR-17-0285. Epub 2017 May 23.

14.

The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.

Ramachandran M, Dimberg A, Essand M.

Semin Cancer Biol. 2017 Aug;45:23-35. doi: 10.1016/j.semcancer.2017.02.010. Epub 2017 Feb 28. Review.

15.

Pleiotrophin is a driver of vascular abnormalization in glioblastoma.

Zhang L, Dimberg A.

Mol Cell Oncol. 2016 Feb 18;3(6):e1141087. doi: 10.1080/23723556.2016.1141087. eCollection 2016.

16.

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment.

Eriksson E, Moreno R, Milenova I, Liljenfeldt L, Dieterich LC, Christiansson L, Karlsson H, Ullenhag G, Mangsbo SM, Dimberg A, Alemany R, Loskog A.

Gene Ther. 2017 Feb;24(2):92-103. doi: 10.1038/gt.2016.80. Epub 2016 Dec 1.

17.

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.

van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, Tötterman TH, Mangsbo SM.

Eur J Immunol. 2017 Feb;47(2):385-393. doi: 10.1002/eji.201646583. Epub 2016 Dec 13.

18.

ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.

Magnusson K, Gremel G, Rydén L, Pontén V, Uhlén M, Dimberg A, Jirström K, Pontén F.

BMC Cancer. 2016 Nov 18;16(1):904.

19.

Pleiotrophin enhances PDGFB-induced gliomagenesis through increased proliferation of neural progenitor cells.

Zhang L, Laaniste L, Jiang Y, Alafuzoff I, Uhrbom L, Dimberg A.

Oncotarget. 2016 Dec 6;7(49):80382-80390. doi: 10.18632/oncotarget.12983.

20.

Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus.

Ramachandran M, Yu D, Dyczynski M, Baskaran S, Zhang L, Lulla A, Lulla V, Saul S, Nelander S, Dimberg A, Merits A, Leja-Jarblad J, Essand M.

Clin Cancer Res. 2017 Mar 15;23(6):1519-1530. doi: 10.1158/1078-0432.CCR-16-0925. Epub 2016 Sep 16.

Supplemental Content

Loading ...
Support Center